Moleculin Biotech announces grant funded research evaluating Annamycin

Moleculin Biotech (MBRX) announced it has entered into research and material transfer agreement with the University of North Carolina at Chapel Hill for investigator-initiated preclinical research evaluating Annamycin for the treatment of pancreatic cancer. Under the terms of the agreement Moleculin will supply Annamycin and William Zamboni, PharmD, PhD, professor at the UNC Eshelman School of Pharmacy, UNC Lineberger Comprehensive Cancer Center, and Carolina Institute of Nanomedicine will conduct the planned preclinical research as part of a series of funded grants. The studies covered under this agreement will evaluate the ability of novel treatment agents and modalities to enhance the tumor delivery of liposomal Annamycin and Free-Annamycin as compared to Doxil and Free-doxorubicin in the PDAC GEMM models.